For the past seven years, the Tax Cuts and Jobs Act (TCJA) has made the United States a more attractive market for jobs and investment primarily by lowering the corporate tax rate from 35 percent to 21 percent while at the same time increasing the cost of earning profits in foreign jurisdictions by imposing a minimum tax, or GILTI tax rate, on all foreign income. As a result, the U.S. business tax system is more globally competitive, helping to foster healthcare innovation and the development of new cures.
With certain TCJA policies recently expired or set to expire this year, Americans are depending on Congress to reinstate the TCJA’s pro-growth tax policies to help protect future cures and American jobs. Acting now will help protect America’s competitive edge.
Patients need Congress to reauthorize the TCJA’s competitive tax policies. Otherwise, there could be serious unintended consequences that harm the resources needed to research, develop, and produce groundbreaking treatments:
By preventing pro-growth TCJA tax policies from expiring and preventing any new anti-competitive provisions from coming into effect, policymakers can help preserve a competitive tax system that not only spurs job growth and the economy but also helps foster healthcare innovation and the development of new cures.
Help protect healthcare innovation and the American workforce: Reauthorize the TCJA tax policies and prevent any new anti-competitive provisions from coming into effect!